Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Chezi Ganzel, Wang Xin Victoria, Adele K. Fielding, MB, BS, PhD, Jacob M. Rowe, MD, Susan M Richards, PhD, Georgina Buck, Rajesh Chopra, PhD, I. Jill Durrant, David Marks, MD PhD, Ian M. Franklin, MD, Andrew K McMilan, Mark R Litzow, MD, Elisabeth Paietta, PhD, Selina Luger, MD, Peter H Wiernik, Dan Douer, MD, Hillard M. Lazarus, MD, Martin S Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2015) 126 (23): 795.

https://doi.org/10.1182/blood.V126.23.795.795

Published: 2015

Journal Articles

Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia

Huimin Geng, PhD, Donna Neuberg, ScD, Elisabeth Paietta, PhD, Xutao Deng, PhD, Yushan Li, Yuan Xin, Janis Racevskis, PhD, Rhett Ketterling, MD, Susan M Richards, PhD, Martin S. Tallman, MD, Jacob M. Rowe, MD, Mark R. Litzow, MD, Olivier Elemento, PhD, Ari M. Melnick

Blood (2010) 116 (21): 852.

https://doi.org/10.1182/blood.V116.21.852.852

Published: 2010

Journal Articles

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Jonathan I Sive, MBChB, Georgina Buck, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 493.

https://doi.org/10.1182/blood.V116.21.493.493

Published: 2010

Journal Articles

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial

Adele K. Fielding, MBBS, PhD, FRCPath, FRCP, Georgina Buck, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Anthony V. Moorman, PhD, Elisabeth Paietta, PhD, Susan M Richards, PhD, Martin S. Tallman, MD, Jacob M. Rowe, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 169.

https://doi.org/10.1182/blood.V116.21.169.169

Published: 2010

Journal Articles

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Mark R. Litzow, MD, Georgina Buck, Gordon Dewald, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Rhett Ketterling, Hillard M. Lazarus, MD, FACP, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Anthony V. Moorman, PhD, Elisabeth Paietta, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 524.

https://doi.org/10.1182/blood.V116.21.524.524

Published: 2010

Journal Articles

Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.

Adele K. Fielding, MBBS, PhD, Susan M. Richards, PhD, Hillard M. Lazarus, MD, Mark R. Litzow, MD, Selina M. Luger, MD, David I. Marks, MBBS, PhD, Andrew K. McMillan, MBBS, PhD, Jacob M. Rowe, MD, Martin S. Tallman, MD, Anthony H. Goldstone, MD

Blood (2007) 110 (11): 8.

https://doi.org/10.1182/blood.V110.11.8.8

Published: 2007

Journal Articles

In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Jacob M. Rowe, MD, Georgina Buck, PhD, Adele Fielding, MD, Martin S. Tallman, MD, Alan K. Burnett, MD, Raj Chopra, MD, Peter H. Wiernik, MD, Susan M. Richards, PhD, Hillard M. Lazarus, MD, Letizia Foroni, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David Marks, MD, Jill Durrant, MD, Anthony H. Goldstone, MD

Blood (2006) 108 (11): 2.

https://doi.org/10.1182/blood.V108.11.2.2

Published: 2006

NARROW

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.

Email alerts

ASH Publications

American Society of Hematology

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only